Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
139,800
Employees139,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
139,800
Employees139,800

JNJ Key Statistics

Market cap
574.79B
Market cap574.79B
Price-Earnings ratio
21.75
Price-Earnings ratio21.75
Dividend yield
2.14%
Dividend yield2.14%
Average volume
8.94M
Average volume8.94M
High today
$240.74
High today$240.74
Low today
$237.04
Low today$237.04
Open price
$240.05
Open price$240.05
Volume
9.38M
Volume9.38M
52 Week high
$240.94
52 Week high$240.94
52 Week low
$141.50
52 Week low$141.50

Stock Snapshot

As of today, Johnson & Johnson(JNJ) shares are valued at $239.04. The company's market cap stands at 574.79B, with a P/E ratio of 21.75 and a dividend yield of 2.1%.

On 2026-02-09, Johnson & Johnson(JNJ) stock traded between a low of $237.04 and a high of $240.74. Shares are currently priced at $239.04, which is +0.8% above the low and -0.7% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 9.38M, against a daily average of 8.94M.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $240.94 at its peak.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $240.94 at its peak.

JNJ News

Benzinga 13h
Johnson & Johnson Reports 90% AFib Freedom In Early Heart Device Study

Johnson & Johnson (NYSE:JNJ) on Friday after hours released data from the OMNY-AF pilot study, a prospective, single-arm, multi-center trial. The study pairs t...

Johnson & Johnson Reports 90% AFib Freedom In Early Heart Device Study
Simply Wall St 1d
Johnson & Johnson Valuation After Strong Q4 Results And US$100b 2026 Growth Ambitions

Johnson & Johnson (JNJ) is back in focus after reporting better than expected fourth quarter results, setting a US$100b 2026 sales goal, and releasing new OMNY...

Johnson & Johnson Valuation After Strong Q4 Results And US$100b 2026 Growth Ambitions
Nasdaq 1d
What is Considered a Good Stock Dividend? 2 Healthcare Stocks That Fit the Bill.

Key Points Reliability is one of the most important things about a dividend. Johnson & Johnson is a Dividend King with an attractive yield. Medtronic is two y...

What is Considered a Good Stock Dividend? 2 Healthcare Stocks That Fit the Bill.

Analyst ratings

57%

of 28 ratings
Buy
57.1%
Hold
35.7%
Sell
7.1%

More JNJ News

TipRanks 3d
Johnson & Johnson presents 12-month pilot-phase data from OMNY-AF study

Johnson & Johnson announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic...

Yahoo Finance 3d
Should Johnson & Johnson’s Expanding Oncology Portfolio Alter the Risk Calculus for JNJ Investors? - Yahoo Finance

...

Should Johnson & Johnson’s Expanding Oncology Portfolio Alter the Risk Calculus for JNJ Investors? - Yahoo Finance
Simply Wall St 3d
ERLEADA Real World Survival Data Adds Weight To Johnson And Johnson Story

Johnson & Johnson (NYSE:JNJ) released new real world evidence on ERLEADA for metastatic castration sensitive prostate cancer. The study reports a significant s...

ERLEADA Real World Survival Data Adds Weight To Johnson And Johnson Story
Simply Wall St 4d
Is It Time To Reassess Johnson & Johnson After Strong Share Price Gains?

If you are asking whether Johnson & Johnson’s current share price still offers value, you are not alone. That is exactly what this article is going to unpack fo...

Is It Time To Reassess Johnson & Johnson After Strong Share Price Gains?
Nasdaq 5d
Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy?

Key Points Johnson & Johnson's growth rate improved this past year, and that trend is likely to continue. The company sees a lot of growth ahead, particularly...

Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy?
Simply Wall St 6d
Johnson & Johnson Cancer And Cardio Advances Underpin Valuation And Momentum

Johnson & Johnson (NYSE:JNJ) reported new real-world data indicating a significant survival benefit for ERLEADA in metastatic castration-sensitive prostate canc...

Johnson & Johnson Cancer And Cardio Advances Underpin Valuation And Momentum
TipRanks 6d
Johnson & Johnson price target raised to $255 from $240 at RBC Capital

RBC Capital raised the firm’s price target on Johnson & Johnson to $255 from $240 and keeps an Outperform rating on the shares. The company is unlikely to undo...

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.